Efficacy and Safety of 0.5 mg/kg/day Starting Dose of Oral Corticosteroids to Treat Bullous Pemphigoid The British Journal of Dermatology

TAKE-HOME MESSAGE

• In this study of 190 patients with bullous pemphigoid, the initial dose of prednisone prescribed was 0.5 mg/kg/day. By day 21, disease control was attained in 75% of patients with mild disease, 68.8% of patients with moderate disease, and 46.4% of patients with severe disease. The 1-year survival rate was 90.9%, 83.0%, and 80.0% for mild, moderate, and severe disease, respectively.

• While the majority of patients with mild and moderate disease responded to a medium dose of prednisone by day 21, less than half of those with severe disease had reached disease control in the same time period at this dose.

–  Caroline K. Crabtree, MD

Abstract

BACKGROUND

European guidelines propose a 0·5 mg kg-1 per day dose of oral prednisone as initial treatment for bullous pemphigoid (BP). We assessed the safety and efficacy of this regimen depending on BP extent and general condition of the patients.

METHODS

In a prospective international study, we consecutively included all patients diagnosed with BP. Patients received a 0·5 mg kg-1 per day dose of prednisone, which was then gradually tapered 15 days after disease control, with the aim of stopping prednisone or maintaining minimal treatment (0·1 mg kg-1 per day) within 6 months after the start of treatment. The two coprimary endpoints were control of disease activity at day 21 and 1-year overall survival. Disease severity was assessed according to the Bullous Pemphigoid Disease Area Index (BPDAI) score.

RESULTS

In total, 198 patients were included between 2015 and 2017. The final analysis comprised 190 patients with a mean age of 80·9 (SD 9·1) years. Control of disease activity was achieved at day 21 in 119 patients [62·6%, 95% confidence interval (CI) 55·3-69.5]; 18 of 24 patients (75%, 95% CI 53·3-90·2), 75 of 110 patients (68·8%, 95% CI 59·2-77·3) and 26 of 56 patients (46.4%, 95% CI 33·0-60·3) had mild, moderate and severe BP, respectively (P = 0·0218). A total of 30 patients died during the study. The overall Kaplan-Meier 1-year survival was 82·6% (95% CI 76·3-87·4) corresponding to 90·9%, 83·0% and 80·0% rates in patients with mild, moderate and severe BP, respectively (P = 0·5). Thresholds of 49 points for BPDAI score and 70 points for Karnofsky score yielded maximal Youden index values with respect to disease control at day 21 and 1-year survival, respectively.

CONCLUSIONS

A 0·5 mg kg-1 per day dose of prednisone is a valuable therapeutic option in patients with mild or moderate BP whose general condition allows them to be autonomous.

The British Journal of Dermatology

International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg-1 per day starting dose of oral corticosteroids to treat bullous pemphigoid

Br J Dermatol 2021 Jun 25;[EPub Ahead of Print], V Hébert, S Bastos, K Drenovska, J Meijer, S Ingen-Housz-Oro, C Bedane, L Lunardon, S Debarbieux, H Jedlickova, F Caux, G Chaby, M D'Incan, C Feliciani, C Boulard, N Schumacher, E Schmidt, A Roussel, MA Richard, J Gottlieb, V Ferranti, O Guérin, J Bénichou, P Joly 

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.